GGrantIndex
← Leaderboards

Joachim J Herz

University Of Texas Sw Med Ctr/Dallas

Google Scholar ↗PubMed ↗ORCID ↗
$19,473,068
Attributed
$22,486,717
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,486,717 · 12

By mechanism

R01$10,942,562 · 4
R37$3,960,033 · 1
P01$3,355,650 · 2
RF1$2,421,962 · 1
RC1$999,749 · 1
R43$498,548 · 1

Top collaborators

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposNeuronsBrainS DiseaseIn VivoApolipoprotein EPhysiologicalLigandsReceptorLow Density Lipoprotein ReceptorBlood VesselsSignal TransductionCellsProteinsBasePathogenesisKnock-OutApolipoprotein E Receptor 2MutantMutationAffectNerve DegenerationTraffickingMediating

Grant awards (50)

Identification of next generation gamma-secretase modulators for Alzheimer's disease$258,213
R41 · FY2025 · AG
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function$238,549
R43 · FY2024 · AG
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function$259,999
R43 · FY2023 · AG
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2022 · NS · contact PI
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2021 · NS · contact PI
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2020 · NS · contact PI
Molecular Basis of Synaptic Suppression by ApoE$405,000
R01 · FY2020 · NS · contact PI
Physiology and Pathophysiology of Apolipoprotein E receptor-2 splicing in Alzheimer's disease$397,171
RF1 · FY2020 · AG · contact PI
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2019 · NS · contact PI
Molecular Basis of Synaptic Suppression by ApoE$405,000
R01 · FY2019 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$400,950
R37 · FY2019 · HL · contact PI
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$814,811
R01 · FY2018 · NS · contact PI
Molecular Basis of Synaptic Suppression by ApoE$405,000
R01 · FY2018 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$400,950
R37 · FY2018 · HL · contact PI
Molecular Basis of Synaptic Suppression by ApoE$405,000
R01 · FY2017 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$400,950
R37 · FY2017 · HL · contact PI
Physiology and Pathophysiology of Apolipoprotein E receptor-2 splicing in Alzheimer's disease$2,024,791
RF1 · FY2016 · AG · contact PI
Molecular Basis of Synaptic Suppression by ApoE$404,166
R01 · FY2016 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$400,229
R37 · FY2016 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$399,713
R37 · FY2015 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$389,550
R37 · FY2014 · HL · contact PI
2014 Neurobiology of Brain Disorders Gordon Research Conference & Gordon Research$50,000
R13 · FY2014 · AG · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$378,420
R37 · FY2013 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$396,771
R37 · FY2012 · HL · contact PI
Cell Signaling, Membrane Cholesterol, and Lipoprotein Receptors$577,248
P01 · FY2011 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$396,250
R37 · FY2011 · HL · contact PI
Cell Signaling, Membrane Cholesterol, and Lipoprotein Receptors$580,011
P01 · FY2010 · HL · contact PI
Enhancing Progranulin Expression - a Therapy for Frontotemporal Dementia$499,999
RC1 · FY2010 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$396,250
R37 · FY2010 · HL · contact PI
Cell Signaling, Membrane Cholesterol, and Lipoprotein Receptors$564,817
P01 · FY2009 · HL · contact PI
Enhancing Progranulin Expression - a Therapy for Frontotemporal Dementia$499,750
RC1 · FY2009 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$332,812
R01 · FY2009 · HL · contact PI
Cell Signaling, Membrane Cholesterol, and Lipoprotein Receptors$564,817
P01 · FY2008 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$332,812
R01 · FY2008 · HL · contact PI
Cell Signaling, Membrane Cholesterol, and Lipoprotein Receptors$564,817
P01 · FY2007 · HL · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$332,812
R01 · FY2007 · HL · contact PI
APO E Receptors and Modulation of Fast Axonal Transport$361,794
R01 · FY2006 · NS · contact PI
Metabolism of the VLDL receptor and ApoE receptor 2$342,752
R01 · FY2006 · HL · contact PI
APO E Receptors and Modulation of Fast Axonal Transport$370,500
R01 · FY2005 · NS
Metabolism of the VLDL receptor and ApoE receptor 2$351,000
R01 · FY2005 · HL
APO E Receptors and Modulation of Fast Axonal Transport$370,500
R01 · FY2004 · NS
METABOLISM OF THE VLDL RECEPTOR AND APOE RECEPTOR 2$292,870
R01 · FY2004 · HL
APO E Receptors and Modulation of Fast Axonal Transport$370,500
R01 · FY2003 · NS
METABOLISM OF THE VLDL RECEPTOR AND APOE RECEPTOR 2$284,468
R01 · FY2003 · HL
APO E Receptors and Modulation of Fast Axonal Transport$370,500
R01 · FY2002 · NS
METABOLISM OF THE VLDL RECEPTOR AND APOE RECEPTOR 2$276,309
R01 · FY2002 · HL
METABOLISM OF THE VLDL RECEPTOR AND APOE RECEPTOR 2$256,793
R01 · FY2001 · HL
LDL RECEPTOR GENE FAMILY$0
P01 · FY2001 · HL
LDL RECEPTOR GENE FAMILY$503,940
P01 · FY2000 · HL
METABOLISM OF THE VLDL RECEPTOR AND APOE RECEPTOR 2$253,439
R01 · FY2000 · HL